APGE Similar Chart Price Prediction
The price of APGE is predicted to go up -5.26%, based on the high correlation periods with LEG. The similarity of these two price pattern on the periods is 95.68%.
APGE
LEG
Down: -5.26%Similarity: 95.68%
APGE Revenue Forecast
APGE EPS Forecast
APGE FAQs
What is bull’s view on APGE?
What is bear's view on APGE?
APGE Analyst's Forecast
David Nierengarten
Wedbush
Buy
2024-12-02
Price Target
$87 → $90
Upside
+96.46%
Wedbush raised the firm's price target on Apogee Therapeutics to $90 from $87 and keeps an Outperform rating on the shares. The firm notes that ahead of its R&D Day, the company announced initial efficacy data for APG777 in AD to come in mid-2025; half-life of 77 days for APG777 and 55 days for IL-4Ralpha mAb APG808; and plans to initiate trials of APG777 for asthma and EoE in the first half of 2025 and 2026, respectively. The company also plans to open an asthma cohort in the Phase 1b trial for APG808, and will open a Dupixent comparator arm in an upcoming trial of APG777 plus APG990 in AD. Wedbush also highlights that Apogee narrowed initiation of a Phase 1 HV trial for APG333 to year-end 2024.
Seamus Fernandez
Guggenheim
Strong Buy
2024-11-27
Price Target
$95 → $110
Upside
+147.8%
Edward Nash
Canaccord Genuity
Strong Buy
2024-11-25
Price Target
$89
Upside
+101.81%
